Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

GenoEye: A machine learning-based framework for the prediction of intermediate eye color phenotypes.

Journal of forensic sciences·2026

Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026

Same author

ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancer.

Molecular cancer research : MCR·2026

Same author

Patient-specific modeling of G2/M cell cycle dynamics reveals prognostic dynamical regimes driven by copy number alterations.

NPJ systems biology and applications·2026

Same author

Clinical advances and practice updates in genitourinary cancers: a 2025 review from the multidisciplinary Spanish 'Cambados annual meeting'.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026

Same author

Could we reduce renal toxicity of [<sup>177</sup>Lu]Lu-PSMA radioligand therapy with furosemide?

European journal of nuclear medicine and molecular imaging·2026

Search research articles

Related Experiment Video

Updated: Apr 23, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Tumor clone dynamics in lethal prostate cancer.

Suzanne Carreira¹, Alessandro Romanel², Jane Goodall¹

¹The Institute of Cancer Research, London SM2 5NG, UK.

Science Translational Medicine

|September 19, 2014

Summary

This summary is machine-generated.

Lethal prostate cancer evolution involves multiple independent clones, not a single dominant one. Monitoring tumor and plasma samples reveals clonal heterogeneity and resistance mechanisms, guiding treatment adjustments.

More Related Videos

Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer

Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer

Published on: June 13, 2019

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Related Experiment Videos

Last Updated: Apr 23, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer

Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer

Published on: June 13, 2019

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Area of Science:

Oncology
Genetics
Cancer Biology

Background:

Prostate cancer metastasis and treatment resistance are complex.
Understanding clonal evolution is crucial for effective cancer management.

Purpose of the Study:

To investigate clonal heterogeneity in lethal prostate cancer progression.
To identify mechanisms of treatment resistance in advanced prostate cancer.

Main Methods:

Sequencing of serial plasma and tumor samples from 16 ERG-positive prostate cancer patients.
Characterization of clonal deletions at 21q22, 8p21, and 10q23.
Analysis of androgen receptor (AR) mutations and their association with clinical progression.

Main Results:

Multiple independent clones were identified in metastatic prostate cancer, with differential representation in tissue and circulation.
Temporal association observed between clinical progression and emergence of AR mutations activated by glucocorticoids.
Resistant clones exhibited complex temporal and spatial heterogeneity, influenced by treatment selection pressure.

Conclusions:

Lethal prostate cancer is characterized by clonal architectural heterogeneity.
Sequential monitoring of plasma and tumor biopsies is essential for managing advanced prostate cancer.
Early discontinuation of ineffective agents can be guided by monitoring clonal dynamics and resistance mechanisms.